EP 1680136 A1 20060719 - PEPTIDES HAVING, FOR EXAMPLE, AN ANTIANGIOGENIC ACTIVITY AND APPLICATIONS THEREOF IN THERAPEUTICS
Title (en)
PEPTIDES HAVING, FOR EXAMPLE, AN ANTIANGIOGENIC ACTIVITY AND APPLICATIONS THEREOF IN THERAPEUTICS
Title (de)
PEPTIDE BEISPIELSWEISE MIT ANTIANGIOGENER WIRKUNG UND IHRE ANWENDUNGEN IN THERAPEUTIKA
Title (fr)
PEPTIDES POSSEDANT NOTAMMENT UNE ACTIVITE ANTI-ANGIOGENIQUE ET LEURS APPLICATIONS EN THERAPEUTIQUE
Publication
Application
Priority
- FR 2004002422 W 20040924
- FR 0311270 A 20030925
Abstract (en)
[origin: US2008171697A1] The invention relates to cyclised peptides corresponding to sequence SEQ ID N<SUP>o</SUP> 1: X<SUB>1</SUB>X<SUB>2</SUB>RGDX<SUB>3</SUB>FGX<SUB>4</SUB>X<SUB>5</SUB>LLFIHFX<SUB>6</SUB>IGSX<SUB>7</SUB>HSX<SUB>8</SUB>IX<SUB>9</SUB>, wherein: the letters without any numerical index correspond to amino acids defined by the single-letter international code; X<SUB>1 </SUB>is G or GG having an amino-terminal end which may or may not be free; X<SUB>2 </SUB>is either a C, in which case X<SUB>2</SUB>=X<SUB>4</SUB>, the two Cs being connected by a disulphide bridge, or X<SUB>2 </SUB>is capable of forming a lactam bridge with X<SUB>4</SUB>, either X<SUB>2 </SUB>or X<SUB>4 </SUB>being an amino acid bearing an acid group, such as A or D, and the other bearing an amino function such as Q, N; X<SUB>3 </SUB>is either an M pattern or a norleucine pattern; X<SUB>5 </SUB>is one or several di-, tri-, or tetra-peptide patterns comprising G or a combination of G and S, or X<SUB>5 </SUB>is a C pattern having a side-chain which serves as a covalent linkage point with a 3-nitro-2-pyridinesulphenyl group which is located at the N-terminal end of the next amino acid (L); X<SUB>6 </SUB>is either an R pattern or a K pattern; X<SUB>7 </SUB>is either an R pattern or a K pattern; X<SUB>8 </SUB>is either an R pattern or a K pattern; and X<SUB>9 </SUB>is an aliphatic amino acid (such as G or A) having an amide C-terminal end. The inventive peptides can be used as active ingredients in medicaments, for example, for the treatment of pathologies linked to hypervascularisation.
IPC 1-7
IPC 8 full level
A61K 38/00 (2006.01); A61K 38/17 (2006.01); A61K 38/18 (2006.01); A61P 9/00 (2006.01); A61P 35/00 (2006.01); C07K 14/00 (2006.01); C07K 14/46 (2006.01); C07K 14/78 (2006.01)
CPC (source: EP US)
A61P 9/00 (2017.12 - EP); A61P 9/10 (2017.12 - EP); A61P 19/02 (2017.12 - EP); A61P 35/00 (2017.12 - EP); C07K 14/001 (2013.01 - EP US); C07K 14/78 (2013.01 - EP US); A61K 38/00 (2013.01 - EP US)
Citation (search report)
See references of WO 2005030238A1
Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR
DOCDB simple family (publication)
US 2008171697 A1 20080717; EP 1680136 A1 20060719; FR 2860236 A1 20050401; FR 2860236 B1 20060106; IL 174547 A0 20060801; JP 2007506713 A 20070322; WO 2005030238 A1 20050407
DOCDB simple family (application)
US 57357604 A 20040924; EP 04787446 A 20040924; FR 0311270 A 20030925; FR 2004002422 W 20040924; IL 17454706 A 20060323; JP 2006527447 A 20040924